Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Alzheimerâ€™s disease
- Brain Waves
- Parkinsons Disease
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 209551
Ampakines are a class of drugs that bind to the glutamatergic AMPA receptor, enhancing its activity by slowing deactivation and attenuating desensitization of AMPA receptor currents, increasing synaptic responses and enhancing LTP.
IPSCIO Record ID: 273373
For the License of Licensor Know-How, Licensor grants to the French Licensee a perpetual, exclusive, even as to Licensor license, with the right to sublicense, to use the Licensor Know How inside the Field, including to develop, have developed, manufacture, have manufactured, use, commercialize, have commercialized, distribute and have distributed for sale and sell Pharmaceutical Specialties in the Territory limited specifically to use with CX1632 or combination products which include CX1632.
Licensor grants an option between the Effective Date and October 31, 2011, exercisable upon written notice from Licensee, to an exclusive, even as to Licensor sublicense, with the right to further sublicense, to use the University License Rights inside the Field, including to further develop, have developed, manufacture, have manufactured, use, commercialize, have commercialized, distribute or have distributed for sale and sell Pharmaceutical Specialties in the Territory.
Licensor grants an exclusive option during the Option Period, exercisable upon written notice from Licensee, to acquire all right, title and interest in and to the Assigned Licensor Patent Rights.
CX1632 comprises a pharmaceutical medicine used for treating memory and cognitive impairments in patients with Alzheimer's disease and other disorders.
IPSCIO Record ID: 299293
Licensee is engaged in the discovery and development of innovative pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders.
IPSCIO Record ID: 300615
IPSCIO Record ID: 294263
Combination Product means any pharmaceutical product which contains one or more pharmacologically or therapeutically active compound(s), product(s) and/or ingredient(s) in addition to Product.
Licensor will remain the sole owner of or otherwise shall continue to control rights in all IP relating to any and all Materials, information, plans or methods, except for Products, that may be disclosed to Licensee or developed solely by Licensor, or licensed to Licensor prior to or separate from performance of the Collaboration (Licensor Existing IP).
All IP conceived in the execution of the Collaboration solely by Licensor, except for Product-related IP, will be owned by Licensor (Licensor New IP)
All IP in the Field conceived in the execution of the Collaboration jointly by Licensor and Licensee, except for Product-related IP, will be owned jointly by Licensor and Licensee (Joint IP), provided that all IP in the Field created solely by any staff at Party A will be owned by Party A and licensed to Licensor under the Party A Agreements, and will be considered part of the Licensor IP licensed to Licensee under this Agreement.